The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia
| Autor: | Agata Wrzesień-Kuś, Tadeusz Robak |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Drug resistance Text mining Refractory Internal medicine medicine Humans Cytotoxic T cell Salvage Therapy Chemotherapy business.industry Optimal treatment Remission Induction Myeloid leukemia Hematology Immunotherapy Prognosis Drug Resistance Neoplasm Leukemia Myeloid Acute Disease business Stem Cell Transplantation |
| Zdroj: | Leukemia & Lymphoma. 43:281-291 |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428190290006053 |
| Popis: | Despite the significant progress in the treatment of AML during the last 5-10 years, 20-40% of patients still do not achieve remission with standard induction therapy. In addition, 50-70% of patients in CR are likely to relapse. A major limitation of successful AML therapy is intrinsic or acquired drug resistance. Several pharmacological inhibitors of mechanisms inducing chemoresistance in leukemic cells have been investigated. New cytotoxic drugs, agents with novel mechanisms of action, and new treatment strategies are currently being investigated. The management of refractory or relapsed AML patients is reviewed in this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|